Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 4 25 W ELECTROLYTES IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 5 5 W O ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 4 25 W ELECTROLYTES IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 5 5 W O ELECTROLYTES.
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER vs TRAVASOL 5.5% W/O ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids serve as substrates for protein synthesis and nitrogen balance; dextrose provides caloric energy for metabolic processes; electrolytes maintain fluid and electrolyte homeostasis.
TRAVASOL 5.5% W/O ELECTROLYTES is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and nitrogen balance in patients unable to tolerate enteral nutrition. It serves as a substrate for gluconeogenesis and other metabolic processes.
Intravenous infusion: 500 mL to 2 L per day, administered via central line at a rate not exceeding 1 mL/min for initial 30 minutes, then increase to 2 mL/min if tolerated. Dose based on patient's protein and energy requirements; typical protein equivalent: 4.25 g/100 mL.
Intravenous infusion, 500 mL to 2000 mL per day as a component of total parenteral nutrition (TPN), providing 5.5% amino acids. Rate should be individualized based on metabolic requirements and tolerance.
None Documented
None Documented
Amino acids: variable, ~10-30 min for most; dextrose: ~1-2 h terminal half-life in healthy adults, prolonged in renal impairment.
Not applicable as a fixed drug; the clearance of infused amino acids follows saturable kinetics with a functional half-life of approximately 30-60 minutes for free amino acids in plasma, reflecting rapid uptake and metabolism. Clinical context: continuous infusion maintains steady-state levels.
Renal excretion of amino acids and dextrose metabolites; >90% of infused amino nitrogen is excreted renally as urea, with minimal biliary/fecal elimination.
Primarily renal excretion of amino acids and metabolites; approximately 70-80% of infused amino acids are converted to urea and excreted in urine, with the remainder undergoing metabolism or incorporation into body proteins. Biliary/fecal excretion is negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution